Coherus Oncology Misses Q1 2026 Revenue Targets Despite LOQTORZI Growth
This article was created with the help of artificial intelligence.
Key Takeaways
- Coherus Oncology reported on May 11, 2026 quarterly revenue of $12.3 million, missing analyst estimates of $14.3 million.
- The adjusted loss per share was $0.25, beating the consensus expectation of $0.27 by 7.41%.
- LOQTORZI sales increased year-over-year by 61% to $11.8 million.
- The company expected important data readouts mid-2026 for pipeline candidates Casdozokitug and Tagmokitug, according to analysts.
- The company's liquidity covers two to three quarters at current cash burn rate, according to a May 13, 2026 SeekingAlpha analysis.
Coherus Oncology (NASDAQ: CHRS) reported on May 11, 2026 total revenue of $12.3 million for the first quarter of 2026, falling short of analyst estimates of $14.3 million. The adjusted loss per share was $0.25, beating the consensus expectation of $0.27 by 7.41%, as reported by Benzinga on the day of release.
LOQTORZI as Revenue Driver
The cancer drug LOQTORZI – a biosimilar – increased sales year-over-year by 61% to $11.8 million, as reported by ChartMill on May 11, 2026. LOQTORZI thus accounts for nearly the entire quarterly revenue. The company focused on oncology following a strategic realignment and previously operated as Coherus BioSciences.
Loss per share improved from the prior-year quarter by 28.57%, when the company had reported a loss of $0.35 per share. Despite this development, Coherus Oncology remains in loss-making territory.
Pipeline Data Expected Mid-2026
The company is working on two pipeline candidates: Casdozokitug and Tagmokitug. Both drug candidates are in clinical trials, and according to ChartMill, Coherus Oncology expects important data readouts mid-2026. The development of these candidates is likely to be crucial for the company's future strategy.
An analysis by SeekingAlpha from May 13, 2026 indicated that the company's liquidity covers two to three quarters at the current cash burn rate. The analysis rated the stock as "Buy," citing upcoming clinical milestones mid-2026 as central to the valuation. Additional financing may be required before these pivotal clinical data become available.
Earnings Call and Investor Communication
Coherus Oncology held an earnings call on May 11, 2026 at 5:00 p.m. EDT. Carrie Graham, Vice President of Investor Relations & Corporate Communications, led the event, as shown in the transcript published by SeekingAlpha on May 12, 2026. The company discussed quarterly results and strategic direction.
The rebranding from Coherus BioSciences to Coherus Oncology reflects the focused alignment on oncology therapeutics. The company is pursuing a dual approach: generating revenue through LOQTORZI while advancing novel antibody therapies.